Denali Therapeutics Inc. (DNLI)
NASDAQ: DNLI · Real-Time Price · USD
21.45
-0.04 (-0.19%)
Dec 20, 2024, 4:00 PM EST - Market closed
Denali Therapeutics Stock Forecast
Stock Price Forecast
The 10 analysts with 12-month price forecasts for Denali Therapeutics stock have an average target of 40.4, with a low estimate of 26 and a high estimate of 90. The average target predicts an increase of 88.34% from the current stock price of 21.45.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for DNLI stock from 11 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 | Dec '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 5 | 6 | 7 |
| Buy | 3 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 1 | 1 | 2 | 2 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Stifel | Stifel | Hold → Strong Buy Upgrades $37 | Hold → Strong Buy | Upgrades | $37 | +72.49% | Dec 16, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +319.58% | Nov 7, 2024 |
| Jefferies | Jefferies | Strong Buy Maintains $40 → $45 | Strong Buy | Maintains | $40 → $45 | +109.79% | Nov 1, 2024 |
| JP Morgan | JP Morgan | Buy Maintains $29 → $28 | Buy | Maintains | $29 → $28 | +30.54% | Oct 11, 2024 |
| Raymond James | Raymond James | Hold Initiates n/a | Hold | Initiates | n/a | n/a | Oct 10, 2024 |
Financial Forecast
Revenue This Year
10.48M
from 330.53M
Decreased by -96.83%
Revenue Next Year
54.51M
from 10.48M
Increased by 420.35%
EPS This Year
-2.85
from -1.06
EPS Next Year
-2.99
from -2.85
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | 52.5M | 164.3M | 545.1M | |||
| Avg | 10.5M | 54.5M | 187.2M | |||
| Low | n/a | n/a | 15.2M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -84.1% | 1,468.8% | 900.0% | |||
| Avg | -96.8% | 420.4% | 243.5% | |||
| Low | - | - | -72.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | -2.69 | -2.17 | -0.72 | |||
| Avg | -2.85 | -2.99 | -2.37 | |||
| Low | -3.08 | -3.43 | -3.59 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|---|
| High | - | - | - | |||
| Avg | - | - | - | |||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.